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Abstract. Cytokines play important roles in the wound 
healing process through various signalling pathways. The 
JAK-STAT pathway is utilised by most cytokines for signal 
transduction and is regulated by a variety of molecules, 
including suppressor of cytokine signalling (SOCS) proteins. 
SOCS are associated with inflammatory diseases and have 
an impact on cytokines, growth factors and key cell types 
involved in the wound-healing process. SOCS, a negative 
regulator of cytokine signalling, may hold the potential 
to regulate cytokine-induced signalling in the chronic 
wound-healing process. Wound edge tissues were collected 
from chronic venous leg ulcer patients and classified as non-
healing and healing wounds. The expression pattern of seven 
SOCSs members, at the transcript and protein level, were 
examined in these tissues using qPCR and immunohistochem-
istry. Significantly higher levels of SOCS3 (P=0.0284) and 
SOCS4 (P=0.0376) in non-healing chronic wounds compared 
to the healing/healed chronic wounds were observed at the 
transcript level. Relocalisation of SOCS3 protein in the non-
healing wound environment was evident in the investigated 
chronic biopsies. Thus, the results show that the expression of 
SOCS transcript indicated that SOCS members may act as a 
prognostic biomarker of chronic wounds.
Introduction
The area of chronic wound healing has drawn much attention 
from many healthcare professionals due to the high cost of 
healthcare resources for patients seeking appropriate treat-
ment, as well as the complexity of its underlying mechanism. 
It has been suggested that a reduction in tissue growth factors, 
an imbalance between proteinases and their inhibitors, and 
the presence of senescent cells is of importance in chronic 
wounds (1). A variety of treatments, such as dressings, appli-
cation of topical growth factors, autologous skin grafting and 
bioengineered skin equivalents have been applied to deal 
with certain types of chronic wounds in addition to the basic 
treatments (1). However, the specific mechanisms of each trea-
ment remain unclear and are under investigation. Therefore, 
more insight into the mechanisms responsible are required 
to gain a better understanding of the wound-healing process. 
Further clarification of this complex system may contribute to 
the emergence of a prognositc marker to predict the healing 
potential of chronic wounds, enhancing patient management.
Wound healing is a dynamic and interactive process that 
is immediately activated by the damage of skin upon injury. 
Primary targets for the treatment of wounds are reducing the 
healing time and generating an aesthetical scar or scar-free 
tissue without comprimising any normal function. The process 
of wound healing consists of three overlapping orchestrated 
stages, known as inflammation, proliferation, and re-epithelial-
ization and tissue remodelling (2). These complex processes are 
regulated by numerous signalling pathways involving several 
cell types including keratinocytes, macrophages, fibroblasts 
and endothelial cells (3). A vast array of cytokines and growth 
factors play key roles in the process of wound healing through 
the initiation of a variety of signalling cascades. Disruption of 
these tightly regulated processes can lead to a variety of patho-
logical conditions. The Janus kinase/signal transducer and 
activator of the transcription (JAK/STAT) pathway is a key 
pathway, responding to a wide variety of cytokines and growth 
factors. Any mutation that holds the potential to compromise 
the regular function of JAK/STAT pathway may affect cyto-
kine stimulated signalling (4). By contrast, loss of regulation 
to this signalling pathway may cause inflammatory disease, 
erythrocytosis, gigantism and leukaemia (5). Therefore, the 
mechanism regulating appropriate JAK/STAT signalling is 
of great importance. This target can be achieved by so-called 
negative regulators, such as Src-homology 2 (SH2) containing 
phosphatase (SHP), protein inhibitors against STATs (PIAS) 
and suppressor of cytokine signalling (SOCS), which all 
comprise specific SH2 domain in their structure (6). However, 
compared to the other two cytokine signalling inhibitors 
which are constitutively expressed, SOCS is the only cytokine 
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inducible inhibitor that may hold the potential to be utilised as 
a regulator for the dysregulation of cell metabolism.
SOCS protein was origninally identified in 1997 
independently by three different groups as SOCS1, the 
JAK-binding protein (JAB) and the STAT-induced STAT 
inhibitor (SSI) (7-9). It was subsequently confirmed that all 
three belong to the SOCS family, which consists of eight 
members [SOCS1 to 7 and cytokine inducible SH2-containing 
protein (CIS)] in mammals (10). Generally, there are three major 
domains contributing to the function of SOCS, identified as a 
central conserved SH2 domain, a N-terminal domain of vari-
able length and divergent sequence, and a carboxy-terminal, 
40-amino-acid module known as SOCS box (11). Some of the 
structurally related eight SOCS family members are capable 
of attenuating cytokine signalling by blocking JAK tyrosine 
kinase activity, competing for a docking site with STAT 
protein and/or binding to the respective target proteins for 
subsequent proteosomal degradation (11). Of the eight SOCS 
family members, CIS/SOCS1 to SOCS3 are the most well 
characterised, whereas, the precise function of the remaining 
four SOCS proteins, SOCS4 to 7, have yet to be elucidated 
due to their extensive expression and inconsistent protein 
targets (12). However, evidence from existing studies show 
that SOCS family members can be classified according to 
their target proteins. CIS/SOCS1 to SOCS3 regulate cytokine 
receptor signalling through the JAK-STAT pathway, whereas 
SOCS4 to 7 are associated with the regulation of growth factor 
receptor signalling (13-15).
The SOCS family members have been found to regulate 
a number of cytokines and growth factors that are essential 
in the wound-healing process (16). With the absence of 
SOCS3, interleukin-6 (IL-6), a proinflammaroty cyto-
kine, acts as an immunosuppressive cytokine that reduces 
tumour necrosis factor (TNF) induced by lipopolysaccha-
rides (LPSs) (17). Additionally, SOCS3 selectively inhibits 
the activation of STAT3 signalling by IL-6, but does not 
influence IL-10-activated STAT3 signalling due to inefficient 
binding to the IL-10 receptor. This potentially explains the 
opposing function of the proinflammatory cytokine IL-6 
and the anti-inflammatory cytokine IL-10, and indicates the 
regulatory role of SOCS3 to IL-6-induced STAT3 signalling, 
highlighting a potential role for SOCS3 in the treatment of 
IL-6-mediated inflammatory diseases (17). The expression of 
SOCS4 and 5 in HeLa cells is induced at the mRNA level 
following treatment with epidermal growth factor (EGF), 
which is frequently induced during the wound-healing 
process. In addition, either SOCS4 or 5 markedly reduces 
EGFR expression (13). This result suggests that SOCS4 
and 5 may have an effect on EGF signalling through the 
regulation of EGFR, the respective receptor of EGF. SOCS5 
is also capable of reducing the expression level of EGFR 
in a ligand- and c-Cbl-independent manner to enhance its 
proteasome degradation. In addition, SH2 and SB domains 
of SOCS5 are required for the regulation of EGFR, which 
enables SOCS5 to attenuate EGF-induced signalling by trans-
locating EGFR to intracellular vesicles (13).
The present study examined the transcript expression 
profile of SOCS1 to 7 in a clinical cohort of healing and non-
healing chronic wounds. This expression was further examined 
in clinical tissue sections to demonstrate their expression 
pattern and localisation in these contrasting subtypes of 
chronic wounds.
Materials and methods
Tissue collection and processing. A clinical chronic wound 
tissue cohort was used in the present study. Tissues were 
collected from patients attending the University Hospital 
of Wales Wound Healing Clinic. Wound edge tissues were 
collected from chronic venous leg ulcer patients following 
ethics approval from a Local Committee (South East Wales 
Research Ethics Committee). Wound size was recorded at the 
time of initial biopsy and was re-measured after 3 months, 
during which wounds were treated as per best medical treat-
ment. Wounds that had become reduced in size over this 
period were described as ‘healing/healed’ (n=20) and those 
which remained static or grew in size were described as 
‘non-healing’ (n=51) chronic wounds. This cohort has been 
previously described (18).
Sample biopsies were snap frozen and stored at -80˚C 
before being placed in liquid nitrogen until required for 
processing and analysis. The samples were sectioned (7 µm) 
on a cryostat (Leica Microsystems, Ltd., Milton Keynes, 
UK), for immunohistochemical (IHC) staining and multiple 
sections (20 µm), were processed for the extraction of RNA, 
reverse transcription and transcript expression analysis using 
quantitative polymerase chain reaction (qPCR).
RNA extraction and reverse transcription. Multiple sections 
from the same patient sample biopsy were combined and 
homogenised in ice-cold TRIzol reagent (Sigma-Aldrich, 
Poole, UK) using a handheld homogeniser (Cole-Parmer, 
London, UK). RNA was subsequently extracted following 
the manufacturer's instructions. Following extraction, RNA 
was resuspended in diethyl pyrocarbonate (DEPC) H2O 
and quantified using a spectrophotometer (WPA UV 1101; 
Biotech Photometer, Cambridge, UK). The samples were then 
standardised prior to undertaking the reverse transcription 
reaction using an RT kit (Bio-Rad, Hemel Hemstead, UK) to 
generate cDNA.
qPCR. qPCR was undertaken to analyse transcript expres-
sion of the SOCS family members in the chronic healing 
and non-healing wound samples. This process has been 
previously described by our laboratory (18,19). In brief, 
primers were designed for each of the SOCS family members 
using the Beacon Designer software (Bio-Rad, Hercules, 
CA, USA). A Z sequence was added to one of each of the 
primer pairs (ACTGAACCTGACCGTACA), to allow incor-
poration of the FAM tagged UniPrimer probe (Intergen, 
Inc., New York, NY, USA) and thus fluorescent detection. 
Expression of the target sequence was detected in conjunction 
with an internal standard used to generate a standard curve. 
The samples were amplified and detected on a StepOnePlus 
qPCR machine (Life Technologies, Paisley, UK), using 
qPCR mastermix (iQ supermix; Bio-Rad), with the specific 
forward primer (10 pM), reverse primer containing the 
Z sequence (1 pM) and the FAM-tagged UniPrimer 
probe (10 pM). SOCS family members were detected in 
conjunction with the cytokeratin 19 (CK19) housekeeping 
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gene and values were subsequently normalised against this 
gene. Primer details are provided in Table I.
IHC staining. Primary antibodies: anti-SOCS1 (sc-9021), 
anti-SOCS2 (sc-9022), anti-SOCS3 (sc-9023), anti-SOCS4 
(sc-68827), anti-SOCS5 (sc-100858), anti-SOCS6 (sc-5608) 
and anti-SOCS7 (sc-8291 and sc-137241) were purchased from 
Insight Biotechnology (Wembley, UK). All the antibodies 
were used at a final concentration of 2 µg/ml.
IHC analysis was performed on a subset of chronic 
wound tissues that included healing/healed (n=10) and 
non-healed (n=10) biopsies. Staining was performed using 
a standard avidin-biotin peroxidase technique. In brief, 
the frozen sections were fixed for 15 min in dried acetone 
(Thermo Fisher Scientific, Ltd., Loughborough, UK) and 
then air dried for 15 min. The sections were washed three 
times in Tris-buffered saline (TBS) for 5 min each, followed 
by a 30-min permeabilisation wash with 0.1% saponin/TBS 
(Sigma-Aldrich). Since this reaction is reversible, subsequent 
washes were performed with 0.1% saponin/TBS. The sections 
were then incubated with a blocking solution in a humidified 
box at room temperature (20-22˚C) for 1 h. The blocking 
solution, which contained 0.1% BSA/0.1% saponin/10% horse 
serum in TBS, was also used to dilute all subsequent reagents. 
Excess blocking solution was removed and the sections were 
incubated with the relevant, previously optimised, primary 
antibody for 1 h. Following washing with 0.1% saponin/TBS, 
the sections were then incubated for 30 min with the relevant 
biotinylated secondary antibody (Vector Laboratories, 
Peterborough, UK), followed by a 30-min incubation with 
the avidin-biotin complex (ABC) reagent. The 3,3'-diamino-
benzidine (DAB) substrate (5 mg/ml) was used to develop the 
final reaction product, the sections were rinsed in tap water, 
counterstained with Gill's hematoxylin (Vector Laboratories), 
and rehydrated through a series of graded alcohols, cleared in 
xylene (Thermo Fisher Scientific, Ltd.) and mounted in DPX 
(Merck Millipore, UK). Negative controls were performed 
where primary antibody was replaced with wash buffer.
Staining was visualised using a microscope, and the locali-
sation and intensity of staining for each antibody was assessed 
by two independent investigators, at both the wound edge and 
an area distal to the wound edge. Intensity of staining was 
qualitatively graded as strong, moderate or negative.
Statistical analysis. Statistical analysis was undertaken 
using the SigmaPlot 11 statistical software package (Systat 
Software Inc., London, UK). Data were analysed using a two-
sample, two-tailed, t-test or a Mann-Whitney test depending 
on data normality. Values of P<0.05 were regarded as statisti-
cally significant.
Results
Expression levels of seven SOCS family members in 
healing/healed and non-healing chronic wounds. The expres-
sion levels of seven SOCS family members were quantified in a 
cohort of venous leg ulcer patients with chronic wounds using 
qPCR (Fig. 1). The expression of each member of the SOCS 
family was obtained between healing/healed and non-healing 
chronic wounds. Compared to healing/healed chronic wounds, 
the non-healing chronic wound tissues had significantly 
higher levels of SOCS3 (P=0.0284) and SOCS4 (P=0.0376) 
transcripts. Similar to the expression levels of SOCS3 and 4, 
the enhanced expression levels of SOCS1, 2, 5 and 6 were 
observed in the non-healing chronic wounds compared to the 
healing/healed chronic wounds. However, the results did not 
show any significant differences (P>0.05). In contrast to the 
trend of expression levels in SOCS1 to 6, the expression level 
of SOCS7 was elevated in the healing/healed chronic wounds 
when compared to that of the non-healing chronic wounds, 
albeit the result was not statistically significant (P>0.05).
Protein expression levels of seven SOCS family members in 
chronic tissues
SOCS1 staining in chronic tissues. The IHC analysis revealed 
the majority of chronic wounds stained positively for SOCS1 
protein (15/20 chronic wounds). Expression of SOCS1 was 
observed in 7/10 healing/healed chronic wounds and 8/10 
non-healing chronic wounds, and therefore there were no 
distinct differences between the two groups. The majority 
of the positive biopsies expressed moderate levels of SOCS1, 
with the exception of one non-healing chronic wound where 
the expression was defined as strong (Fig. 2).
A comparison of SOCS1 expression at the wound edge to that 
observed distal to the wound (towards normal tissue) revealed 
that 6/20 biopsies had an increased expression of SOCS1 distal 
to the wound edge, although no difference was evident between 
Table I. Primers used in the present study.
Primers Forward Reverse
SOCS1 5'-GATGGTAGCACACAACCAG 5'-ACTGAACCTGACCGTACAGAGGAGGAGGAGGAAGGTT
SOCS2 5'-GGATGGTACTGGGGAAGTAT 5'-ACTGAACCTGACCGTACATGGGAGCTATCTCTAATCAA
SOCS3 5'-TCAAGACCTTCAGCTCCA 5'-ACTGAACCTGACCGTACAGTCACTGCGCTCCAGTAG
SOCS4 5'-GGCAGTGTTTTCCAATAAAG 5'-ACTGAACCTGACCGTACAAGGTGGGAAAGGACACTTAT
SOCS5 5'-AGTCAAAGCCTCTCTTTTCC 5'-ACTGAACCTGACCGTACACATTTTGGGCTAAATCTGA
SOCS6 5'-CCTTACAGAGGAGCTGAAAA 5'-ACTGAACCTGACCGTACACGAAAAGAAAAGAACCATC
SOCS7 5'-CAGGCCCTGAATTACCTC 5'-ACTGAACCTGACCGTACAGAGGTTGCTGCTGCTGCT
CK19 5'-AGCCACTACTACACGACCAT 5'-ACTGAACCTGACCGTACATCGATCTGCAGGACAATC
ACTGAACCTGACCGTACA represents the Z sequence. SOCS, suppressor of cytokine signalling; CK19, cytokeratin 19.
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the healing/healed and non-healing groups (3/10 healing/healed 
and 3/10 non-healed). Generally, in the chronic wounds, diffuse 
cytoplasmic staining was observed in the mature keratinocytes 
of the epidermis, although increasing nuclear and cytoplasmic 
intensity in the basal layer distal to the wound edge was identi-
fied. Most blood vessels were weakly positive for SOCS1 in all 
the biopsies analysed. Positive staining was also observed in 
the dermal inflammatory infiltrate of some biopsies, but dual 
fluorescent staining was required to determine whether these 
were T-lymphocytes, macrophages, fibroblasts or other cells.
SOCS2 staining in chronic tissues. SOCS2-positive 
staining was found in 17/20 chronic wound biopsies studied, 
8/10 healing/healed and 9/10 non-healing biopsies, respec-
tively. The majority of these positively stained biopsies 
exhibited SOCS2 expression of moderate intensity, albeit 
3/20 revealed stronger intensity (2/10 healing/healed, 
1/10 non-healing) (Fig. 3). Three of the positively stained 
biopsies showed SOCS2 expression in the dermal cell infil-
trate, while no expression was observed in the epidermis.
SOCS2 protein expression was uniform throug hout the 
whole biopsy, with only four chronic wounds showing differ-
ences between the wound edge and distal to the wound (3/10 
healing/healed, 1/10 non-healing). Within the healing/healed 
subset, two of these biopsies showed an increased expression 
distal to the wound edge, whereas the other subset demonstrated 
an increased SOCS2 in the dermal infiltrate directly below the 
leading migratory epidermis (which was negatively stained).
Expression of SOCS2 protein was generally observed as 
diffuse cytoplasmic in mature keratinocytes, or nuclear in the 
lower keratinocytes of the basal layer. Membranous staining 
was observed in the very mature keratinocytes of some biopsies.
SOCS3 staining in chronic tissues. Positive SOCS3 staining 
was observed in the non-healing chronic wounds (10/10), and 
in the majority of healing/healed chronic wounds (8/10). Most 
Figure 1. Transcript levels of suppressor of cytokine signalling 1 (SOCS1) (top panel left), SOCS2 (top panel middle), SOCS3 (second panel middle), 
SOCS4 (second panel right), SOCS5 (top panel right), SOCS6 (second panel left) and SOCS7 (bottom panel) in wound tissues. The expression of each SOCS 
family is normalised by the expression of cytokeratin 19 (CK19), *P<0.05.
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Figure 2. Immunohistochemical (IHC) evaluation of the suppressor of cytokine signalling 1 (SOCS1) protein in healing/healed wounds (top two panels) and 
non-healing wounds (bottom three panels). Each group shows representative images from collected biopsies, showing moderate SOCS1 staining and different 
protein distribution between wound edge and distal areas at two magnifications (x10 and x20). Representative images of non-healing sections demonstrate 
areas of strong and moderate staining as well as protein distribution (bottom panels). 
Figure 3. Immunohistochemical (IHC) evaluation of the suppressor of cytokine signalling 2 (SOCS2) protein in healing/healed wounds (top three panels) 
and non-healing wounds (bottom three panels). Each group shows representative images from the collected biopsies demonstrating strong staining, moderate 
staining and different protein distribution between wound edge and distal area at two magnifications (x10 and x20) within the sections.
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of the positively stained biopsies exhibited SOCS3 staining of 
moderate intensity (5/10 healing/healed, 8/10 non-healing), but 
strong staining was observed in 3/10 healing/healed and 2/10 
non-healing wounds (Fig. 4).
Five of the chronic wounds studied showed increased 
expression of SOCS3 protein in the epidermis distal to 
the wound edge, and interestingly the majority of these 
were non-healing chronic wounds (1/10 healing/healed, 
4/10 non-healing), suggesting a trend of increased expression 
and relocalisation of SOCS3 in the non-healing wound envi-
ronment. The remaining 15/20 chronic wounds studied had 
uniform epidermal staining throughout the biopsies.
SOCS3 expression was seen as diffuse cytoplasmic staining 
in the mature keratinocytes or nuclear in the lower basal 
and suprabasal layers, particularly distal to the wound edge. 
Many inflammatory cells within the dermis also expressed 
SOCS3, particularly below the leading wound edge (migratory 
epidermis) and around the blood vessels.
SOCS4 staining in chronic tissues. The SOCS4 protein 
expression was observed in almost all the chronic wound 
biopsies studied (18/20), and no distinct differences were 
evident between the two subsets (9/10 healing/healed, 
9/10 non-healing). The majority of chronic wounds had uniform 
staining of moderate intensity throughout the biopsies (16/20), 
and only two samples exhibited increased (strong) staining for 
SOCS4 (1/10 healing/healed, 1/10 non-healing) (Fig. 5).
Increased expression of SOCS4 distal to the wound 
edge was evident in 5/10 chronic wounds examined, and 
this was observed in the healing and non-healing wounds 
(3/10 healing/healed, 2/10 non-healing).
SOCS4 expression was mostly localised to the nucleus 
of the lower basal and suprabasal cells of the epidermis, but 
diffuse cytoplasmic staining was also observed in the very 
mature upper keratinocyte layers.
SOCS5 staining in chronic tissues. Staining of SOCS5 protein 
was generally less compared to that observed for the other SOCS 
proteins, but was obseved in almost all the chronic wounds 
studied (8/10 healing/healed, 8/10 non-healing) (Fig. 6). 
Uniform expression was observed in the two subsets, albeit 
2/10 non-healing biopsies showed an increased SOCS5 expres-
sion distal to the wound edge. SOCS5 staining was mainly 
cytoplasmic, and observed in all the layers of the epidemis.
SOCS6 staining in chronic tissues. SOCS6 protein expres-
sion was observed in 12/20 chronic wounds, equally in the 
healing/healed (6/10) and non-healing chronic wounds (6/10). 
The IHC analysis revealed the staining to be of moderate inten-
sity in most biopsies (5/10 healing/healed, 5/10 non-healing), 
Figure 4. Immunohistochemical (IHC) evaluation of the suppressor of cytokine signalling 3 (SOCS3) protein in healing/healed wounds (top three panels) 
and non-healing wounds (bottom three panels). Each group shows representative images from the collected biopsies, demonstrating strong staining, moderate 
staining and different protein distribution between wound edge and distal area at two magnifications (x10 and x20) within the sections.
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with only two biopsies showing particularly stronger expres-
sion of SOCS6 (1/10 healing/healed, 1/10 non-healing (Fig. 7).
Increased SOCS6 expression was identified in the 
epidermal layers distal to the wound edge in 4/20 biopsies 
Figure 5. Immunohistochemical (IHC) evaluation of the suppressor of cytokine signalling 4 (SOCS4) protein in healing/healed wounds (top three panels) and 
non-healing wounds (bottom three panels). Each group shows representative images from the collected biopsies, which are strong staining, moderate staining 
and different protein distribution between wound edge and distal area at two magnifications (x10 and x20) within the sections.
Figure 6. Immunohistochemical (IHC) evaluation of the suppressor of cytokine signalling 5 (SOCS5) protein in healing/healed wounds (top one panel) and 
non-healing wounds (bottom two panels). The top panel shows representative images of moderate staining detected for SOCS5 in 10 collected healing/healed 
biopsies. The bottom two panels show representative images from collected non-healing biopsies, demonstrating moderate staining and different protein 
distribution between wound edge and distal area at two magnifications (x10 and x20) within the sections.
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examined (2/10 healing/healed, 2/10 non-healing), although 
the remaining biopsies showed uniform staining throughout 
the tissue samples.
The nucleus of basal and suprabasal keratinocyte cells 
were particularly positive for SOCS6. However, cytoplasmic 
staining in other layers was also observed.
SOCS7 staining in chronic tissues. SOCS7 expression was 
examined throughout the healing/healed and the non-healed 
chronic wound tissue sections. The sections demonstrated no 
significant staining profiles when tested with either of the two 
antibodies available within our laboratories (data not shown). 
Thus, this molecule appears to demonstrate weak to no expres-
sion in the tissues tested in the present study.
Discussion
Cytokines play important roles in the wound-healing process 
by attracting inflammatory cells, inducing cell proliferation, 
differentiation and maturation through various signalling 
pathways (2,3). Due to these essential roles, some cytokine inter-
vention therapies, such as the usage of platelet-derived growth 
factor (PDGF) for non-infected foot ulcers, have been licensed 
and clinically used on diabetic patients (1). However, the mixed 
presence of cytokines and growth factors at the wound site is 
concentration- and time-dependent. Therefore, more focused 
therapies using multiple cytokines and growth factors and/or 
in a time-specific manner may provide an effective strategy. 
Such strategies are beginning to be realised and one therapeutic 
method, termed cytokine gene therapy, has shown the ability to 
topically deliver strategic cytokines and growth factors at precise 
time points during the wound-healing process and demonstrates 
effectiveness in improving the healing of the wounds that have 
specific genetic defects (20,21). Given the significance of cytokine 
signalling in wound healing, dysregulation of such signalling 
may enhance the risk of pathologic and abnormal conditions, 
potentially leading to delayed healing or non-healing chronic 
wounds. The JAK-STAT pathway is utilised by most cytokines 
for signal transduction and is subject to regulation by a number of 
other molecules including SOCS proteins (5). Therefore, the aim 
of the present study was to assess the expression pattern of the 
seven SOCS family members within a clinical cohort of healing 
and non-healing chronic wounds to examine their potential to act 
as biomarkers for predicting healing progression.
Our present data, involving the screening of a clinical 
cohort for the transcript expression of seven SOCS members, 
show that differences in expression of SOCS family members 
were observed between the healing/healed and non-healing 
chronic wounds. Notably, significant differences were 
obtained for the expression of SOCS3 and 4 between the two 
Figure 7. Immunohistochemical (IHC) evaluation of the suppressor of cytokine signalling 6 (SOCS6) protein in healing/healed wounds (top three panels) 
and non-healing wounds (bottom three panels). Each group shows representative images from the collected biopsies, demonstrating strong staining, moderate 
staining and different protein distribution between wound edge and distal area at two magnifications (x10 and x20) within the sections.
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groups of chronic wounds. In addition, gene level screening 
performed in the present study suggested that higher, albeit 
not significant, expression of SOCS1, 2, 5 and 6 in chronic 
venous leg ulcer patients may indicate poor healing prognosis, 
whereas a decreased expression of SOCS7 transcript may 
suggest higher healing potential. However, the low levels of 
SOCS7 protein expression detected in our study may limit this 
significance and requires further clarification. Additionally, 
screening seven members of the SOCS family in chronic 
wound biopsy sections using IHC analysis did not reveal any 
obviously distinct differences between the non-healing and 
healing/healed chronic wounds and in some ways contrasts 
our transcript analysis. These differences may be due to the 
smaller subset of samples used in the IHC analysis than in the 
qPCR analysis. The discrepancy may also have arisen due to 
the qualitative nature of the IHC study or may be some aspect 
of post-transcriptional regulation.
SOCS family members have been previously linked to 
inflammatory disorders and diseases. For example, studies on 
SOCS1-deficient mouse models have suggested that SOCS1 is 
an important modulator of interferon-γ (IFN-γ) and allows it 
to exert protective effects without the risk of hyper-response to 
viral infection (22). Some of the biopsies in the current study 
had positive SOCS1 staining in the dermal inflammatory infil-
trate. Such results suggested that SOCS1 helps inflammatory 
cell infiltrate, leading to a prolonged inflammation phase, a 
major cause of chronic wounds (2). However, dual fluorescent 
staining may be required to identify whether these positively 
stained cells were T-lymphocytes, macrophages, fibroblasts 
or other cells.
SOCS3, acting as an anti-inflammatory regulator, medi-
ates IL-6-gp130 signalling by preventing the activation of 
STAT3 in macrophages (23,24). Given that chronic inflam-
matory diseases are promoted by IL-6 and IL-6-related 
cytokine-mediated STAT3 pathways, and that the expression 
of SOCS3 is able to inhibit STAT3 activation, it appears that 
SOCS3 holds the potential to regulate inflammatory diseases 
related to IL-6 activation (25). Additionally, SOCS3 was 
found to be a negative regulator of IFN-γ-induced signal-
ling through the suppression of activated STAT1 (26). In the 
present study, SOCS3 expression was observed in the cyto-
plasmic region of mature keratinocytes or the nuclear region 
in the lower basal and suprabasal layers, particularly distal to 
the wound edge. SOCS3 expression was also found in inflam-
matory cells in the dermis below the migratory epidermis 
and around blood vessels in chronic wound biopsies. This 
differential SOCS3 expression pattern over different areas 
of the wound biopsies may indicate a differential regulatory 
role for SOCS3 in different stages of the wound healing 
process, although further investigation is required to identify 
the specific molecule(s) or downstream signalling pathway(s) 
that may be regulated by SOCS3.
Concerning SOCS5, findings of in vitro studies on the 
development of helper T cells suggest that this protein is 
involved in impairing IL-4-induced STAT6 activation by 
preferentially interacting with the IL-4 receptor, irrespective 
of receptor tyrosine phosphorylation. The development of 
helper T2 (Th2) cells is known to be regulated by cytokine 
signalling through the IL-4 receptor. Therefore, SOCS5 may 
act as a negative regulator of Th2 development by blocking 
IL-4 signalling (27). There was only moderate staining 
for SOCS5 protein in the healing/healed and non-healing 
chronic wound biopsies compared to that of the other SOCS 
family members examined in the present study. This result 
suggests a lower expression pattern of SOCS5 in chronic 
wound healing relative to the other members. Additionally, 
SOCS5 staining was mainly observed in the cytoplasmic 
region in all the layers of the epidemis, which may indicate 
its regulatory role in keratinocyte behaviour during wound 
healing.
Furthermore, the proliferation and re-epithelialization 
phases of wound healing consist of neoangiogenesis, 
granulation tissue formation, extracellular matrix deposition 
and re-epithelialization (2). Keratinocytes are important in 
this stage through the function of migration, proliferation and 
differentiation. They are defined as major cell components of 
the epidermis, not only for the function of barrier maintenance, 
but for its restoration following injury (28). Dysregulation 
of keratinocyte migratory function is associated with the 
clinical phenotype of chronic non-healing wounds (29). 
Direct evidence indicates that SOCS proteins may hold the 
potential to influence the wound-healing process by regulating 
the wound site resident cell function. Studies have shown 
that keratinocyte proliferation and migration are strongly 
disturbed by the presence of SOCS3, which contributes 
to impaired wound healing (30), whereas the exacerbated 
inflammation that characterises chronic wounds is shown to 
be associated with the overexpression of SOCS3 (31). This 
evidence may explain the significantly increased expression 
of SOCS3 transcript levels in the non-healing chronic wound 
biopsies compared to that in the healing/healed chronic wound 
biopsies, indicating the upregulation of SOCS3 in non-healing 
chronic wounds. The IHC staining results on the profile of 
SOCS3 protein expression, and the distinct proportion (1:4) 
of the increased SOCS3 protein expression in the epidermis 
distal to the wound edge throughout 20 chronic wound biospies 
(1/10 healing/healed, 4/10 non-healing) are noteworthy. They 
suggest loss of SOCS3 expression on the leading migratory 
epidermis in the healing/healed chronic wound and/or the 
relocation of SOCS3 protein between healing/healed and 
non-healing chronic wounds.
Taken together, SOCS proteins are attractive molecules 
that may act as novel biomarkers and/or therapeutics to manage 
chronic wounds, although additional study is required to fully 
elucidate this role. Thus, establishment of a larger cohort of 
these tissues, as well as exploring SOCS function and expres-
sion across acute and chronic wound tissue and normal skin 
is required. Additionally, future investigations are required, 
using in vitro and in vivo models, to determine the potential 
functional traits of SOCS3 and 4 in representative cell types 
which play essential roles in the wound-healing process. Such 
studies may provide additional detail with regard to the precise 
nature of the SOCS family in the wound-healing process and 
their true potential to act as novel strategies to combat and 
manage wound chronicity.
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